Skip to main content
Premium Trial:

Request an Annual Quote

Frank Lee, former CTO at Millennium Pharmaceuticals, to Lead Bioengineering Start-up EngeneOS

NEW YORK, March 2 - Former Millennium Pharmaceuticals chief technology officer Frank Lee has joined EngeneOS, a start-up biomolecular engineering company based in Cambridge, Mass.

Lee will become president and CEO of EngeneOS (pronounced ingenious), which counts Eric Lander as a member of its scientific advisory board. The company hopes to develop molecular machines using a combination of genomics, biotechnology, and the physical sciences, Lee said.

"The whole idea of the company is to take advantage of the wealth of genomic information, and combine it with other disciplines like physics, engineering, and electronics," said Lee.

After six years at Millennium as a member of the original management team, Lee said he was ready for a new challenge. "I had a great time [at Millennium], but last fall I decided to step back and think about doing something different."

At EngeneOS, Lee said he will build the science and technology base of the company, as well as develop its financing and commercial structure.

In the short term, EngeneOS is hoping to develop programmable biomolecular machines that might serve specific purposes, such as acting as biosensors, but in the long term, the company hopes to create a tool set--analogous to CAD, or computer-aided-design--that could be licensed to others.

EngeneOS is backed by Newcogen, a Cambridge-based venture capital firm founded by Noubar Afeyan, who helped start Celera Genomics.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.